Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study

Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study

Background Hepatitis B virus (HBV) reactivation with a hepatitis flare is a common complication in lymphoma patients treated with immunotherapy and/or chemotherapy. Anti-HBV prophylaxis is suggested for non-Hodgkin lymphoma (NHL) patients undergoing rituximab therapy, even those with resolved HBV in...

Full description

Bibliographic Details
Main Authors: Yu-Fen Tsai, Ching-I Yang, Jeng-Shiun Du, Ming-Hui Lin, Shih-Hao Tang, Hui-Ching Wang, Shih-Feng Cho, Yi-Chang Liu, Yu-Chieh Su, Chia-Yen Dai, Hui-Hua Hsiao
Format: Article
Language:English
Published: PeerJ Inc. 2019-09-01
Series:PeerJ
Subjects:
Non-Hodgkin lymphoma
Rituximab
HBV reactivation
HBsAg-positive
Resolved HBV infection
Online Access:https://peerj.com/articles/7481.pdf

Internet

https://peerj.com/articles/7481.pdf

Similar Items